Mayo Clinic

In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 13, 2024), Mayo Clinic reported 5 stock positions worth $6.1 million. Its top holding was Zentalis Pharmaceuticals (ZNTL) at 48.0% of the portfolio, followed by iShares MSCI Acwi ETF (ACWI, 31.1%) and Perspective Therapeutics (CATX, 14.0%). Compared with Q4 2023, it opened 1 new position, sold out of 3 and reduced 1. The biggest buy was a new position in Perspective Therapeutics (CATX) and the biggest sale iShares MSCI Acwi ETF (ACWI, shares −85%).

Most Recent 13F
Q3 2024
Location
Rochester, MN
CIK
0001318153
Portfolio Value
$6.1M (Q1 2024)
SEC Filing
0000950123-24-004535 ↗ filed May 13, 2024

Holdings Value

0$2.0M$4.0M$6.0M$8.0M Q1 2024: $6.1M $6.1M Q1 2024 Q2 2024: $3.0M Q2 2024 Q3 2024: $2.9M Q3 2024

Holdings 5 stocks · $6.1M
ZNTL Zentalis Pharmaceuticals Inc. 48.00% 187,143 $2.9M No change
ACWI iShares MSCI Acwi ETF 31.11% 17,359 $1.9M Reduce -84.7%
CATX Perspective Therapeutics Inc. 14.03% 724,641 $862K New
NEUROONE MED TECHNOLOGIES CO 3.55% 181,754 $218K No change
UNBX Unity Biotechnology Inc. 3.31% 124,081 $203K No change

Portfolio Sells Q4 2023 → Q1 2024
ACWI iShares MSCI Acwi ETF Reduce -84.7% 31.11% −40.38
IMNM Immunome Inc. Sold out 0.00% −7.17
SCLX Scilex Holding Co. Sold out 0.00% −0.53
IBRX Immunitybio Inc. Sold out 0.00% −0.04

Portfolio Buys Q4 2023 → Q1 2024
CATX Perspective Therapeutics Inc. New 14.03% +14.03

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2024 3$2.9MACWI, ZNTL, UNBX
Q2 2024 4$3.0MACWI, ZNTL, UNBX, NEUROONE MED TECHNOLOGIES CO
Q1 2024 5$6.1MZNTL, ACWI, CATX, NEUROONE MED TECHNOLOGIES CO, UNBX